These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 32640259)

  • 1. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
    Kumagai S; Togashi Y; Sakai C; Kawazoe A; Kawazu M; Ueno T; Sato E; Kuwata T; Kinoshita T; Yamamoto M; Nomura S; Tsukamoto T; Mano H; Shitara K; Nishikawa H
    Immunity; 2020 Jul; 53(1):187-203.e8. PubMed ID: 32640259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
    Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13
    Hu C; You W; Kong D; Huang Y; Lu J; Zhao M; Jin Y; Peng R; Hua D; Kuang DM; Chen Y
    Gastroenterology; 2024 Jun; 166(6):1069-1084. PubMed ID: 38445519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
    Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H
    Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
    Kumagai S; Koyama S; Itahashi K; Tanegashima T; Lin YT; Togashi Y; Kamada T; Irie T; Okumura G; Kono H; Ito D; Fujii R; Watanabe S; Sai A; Fukuoka S; Sugiyama E; Watanabe G; Owari T; Nishinakamura H; Sugiyama D; Maeda Y; Kawazoe A; Yukami H; Chida K; Ohara Y; Yoshida T; Shinno Y; Takeyasu Y; Shirasawa M; Nakama K; Aokage K; Suzuki J; Ishii G; Kuwata T; Sakamoto N; Kawazu M; Ueno T; Mori T; Yamazaki N; Tsuboi M; Yatabe Y; Kinoshita T; Doi T; Shitara K; Mano H; Nishikawa H
    Cancer Cell; 2022 Feb; 40(2):201-218.e9. PubMed ID: 35090594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6
    De Wispelaere W; Annibali D; Tuyaerts S; Messiaen J; Antoranz A; Shankar G; Dubroja N; Herreros-Pomares A; Baiden-Amissah REM; Orban MP; Delfini M; Berardi E; Van Brussel T; Schepers R; Philips G; Boeckx B; Baietti MF; Congedo L; HoWangYin KY; Bayon E; Van Rompuy AS; Leucci E; Tabruyn SP; Bosisio F; Mazzone M; Lambrechts D; Amant F
    Clin Transl Med; 2024 May; 14(5):e1655. PubMed ID: 38711203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased tumor-infiltrating CD45RA
    Mao FY; Kong H; Zhao YL; Peng LS; Chen W; Zhang JY; Cheng P; Wang TT; Lv YP; Teng YS; Fu XL; Liu YG; Wu XL; Hao CJ; You N; Luo P; Yu PW; Zou QM; Guo G; Zhuang Y
    Cell Death Dis; 2017 Aug; 8(8):e3002. PubMed ID: 28817117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
    Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
    Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
    Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
    Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
    Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
    Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
    Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
    Front Immunol; 2021; 12():793831. PubMed ID: 34987517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise Training Improves Tumor Control by Increasing CD8
    Gomes-Santos IL; Amoozgar Z; Kumar AS; Ho WW; Roh K; Talele NP; Curtis H; Kawaguchi K; Jain RK; Fukumura D
    Cancer Immunol Res; 2021 Jul; 9(7):765-778. PubMed ID: 33839688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3Kαδ Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model.
    Chang WI; Han MG; Kang MH; Park JM; Kim EE; Bae J; Ahn S; Kim IA
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):845-858. PubMed ID: 33642128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
    Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1-Mediated PI3K/Akt/mTOR, Caspase 9/Caspase 3 and ERK Pathways Are Involved in Regulating the Apoptosis and Proliferation of CD4
    Liu Y; Liu S; Wu C; Huang W; Xu B; Lian S; Wang L; Yue S; Chen N; Zhu Z
    Front Immunol; 2020; 11():467. PubMed ID: 32256500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
    Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
    Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment.
    Banerjee H; Nieves-Rosado H; Kulkarni A; Murter B; McGrath KV; Chandran UR; Chang A; Szymczak-Workman AL; Vujanovic L; Delgoffe GM; Ferris RL; Kane LP
    Cell Rep; 2021 Sep; 36(11):109699. PubMed ID: 34525351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
    Budhu S; Schaer DA; Li Y; Toledo-Crow R; Panageas K; Yang X; Zhong H; Houghton AN; Silverstein SC; Merghoub T; Wolchok JD
    Sci Signal; 2017 Aug; 10(494):. PubMed ID: 28851824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.